CK-103 is an investigational oral, small molecule inhibitor of bromodomain and extra-terminal (“BET”) bromodomains. A bromodomain is an amino acid protein domain that recognizes acetylated-lysine. The binding of the drug prevents interaction between BET proteins and both acetylated histones and transcription factors.
Scientific literature has shown that small molecule inhibition of BET bromodomains may lead to selective killing of tumor cells across certain targeted solid tumors. In May 2016, we entered into an exclusive license agreement with Jubilant Biosys Limited to develop and commercialize novel compounds that inhibit BET bromodomains on a worldwide basis.
We plan to develop CK-103 for the treatment of various advanced and metastatic solid tumor cancers, including, but not limited to, those associated with elevated c-Myc expression.